PMID- 27502495
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160908
LR  - 20201001
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 7
IP  - 3
DP  - 2016 Sep
TI  - Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes 
      Mellitus and Renal Impairment.
PG  - 439-54
LID - 10.1007/s13300-016-0189-4 [doi]
AB  - INTRODUCTION: Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used in the 
      management of patients with type 2 diabetes mellitus (T2DM) and renal impairment 
      (RI). A systematic literature review was performed to compare the efficacy and 
      safety of DPP-4 inhibitors in patients with T2DM and RI. METHODS: We searched 
      EMBASE, MEDLINE, and the Cochrane Central Register of Controlled Trials (cut-off, 
      June 2015) to identify >/=12-week, randomized, placebo-controlled trials on DPP-4 
      inhibitors in >/=50 patients with T2DM and RI. Outcomes of interest included change 
      in glycated hemoglobin (HbA1c), overall safety, and incidence of hypoglycemic 
      events (HEs). RESULTS: Seven trials of </=52-54 weeks duration were retrieved, 
      which included one study each on vildagliptin, saxagliptin, and sitagliptin, two 
      on linagliptin, and the remaining two were extension studies of vildagliptin and 
      saxagliptin. Majority of patients were on insulin at baseline (53-86%), except in 
      the sitagliptin study, where approximately 11% received insulin during the 
      placebo-controlled phase. After 52 weeks, vildagliptin and saxagliptin reduced 
      HbA1c levels by 0.6-0.7% (baseline 7.8-8.4%) versus placebo in the overall 
      population. HbA1c reductions were similar at weeks 12 and 52. In the 12-week, 
      placebo-controlled phase, sitagliptin and linagliptin reduced mean HbA1c by 
      approximately 0.4% (baseline 7.7-8.1%) versus placebo. Rates of HEs with DPP-4 
      inhibitors were not significantly different versus placebo in any study. Rates of 
      adverse events (AEs) and changes involving renal function were similar in the 
      active- and placebo-treated groups. CONCLUSION: These results suggest that DPP-4 
      inhibitors have the potential to improve glycemic control in patients with RI 
      without increasing the risk of HEs or overall AEs. FUNDING: Novartis Pharma AG.
FAU - Thomas, Merlin C
AU  - Thomas MC
AUID- ORCID: 0000-0002-2478-3586
AD  - Baker IDI Heart and Diabetes Institute, Melbourne, Australia. 
      merlin.thomas@bakeridi.edu.au.
FAU - Paldanius, Paivi M
AU  - Paldanius PM
AD  - Novartis Pharma AG, Basel, Switzerland.
FAU - Ayyagari, Rajeev
AU  - Ayyagari R
AD  - Analysis Group Inc., Boston, MA, USA.
FAU - Ong, Siew Hwa
AU  - Ong SH
AD  - Novartis Pharma AG, Basel, Switzerland.
AD  - Vifor Pharma Ltd., Glattbrugg, Switzerland.
FAU - Groop, Per-Henrik
AU  - Groop PH
AD  - Baker IDI Heart and Diabetes Institute, Melbourne, Australia.
AD  - Abdominal Centre Helsinki, University of Helsinki and Helsinki University 
      Hospital, Helsinki, Finland.
AD  - Folkhalsan Institute of Genetics, Folkhalsan Research Centre, Biomedicum 
      Helsinki, Helsinki, Finland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160808
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC5014795
OTO - NOTNLM
OT  - DPP-4 inhibitors
OT  - Linagliptin
OT  - Saxagliptin
OT  - Sitagliptin
OT  - Type 2 diabetes mellitus
OT  - Vildagliptin
EDAT- 2016/08/10 06:00
MHDA- 2016/08/10 06:01
PMCR- 2016/08/08
CRDT- 2016/08/10 06:00
PHST- 2016/05/18 00:00 [received]
PHST- 2016/08/10 06:00 [entrez]
PHST- 2016/08/10 06:00 [pubmed]
PHST- 2016/08/10 06:01 [medline]
PHST- 2016/08/08 00:00 [pmc-release]
AID - 10.1007/s13300-016-0189-4 [pii]
AID - 189 [pii]
AID - 10.1007/s13300-016-0189-4 [doi]
PST - ppublish
SO  - Diabetes Ther. 2016 Sep;7(3):439-54. doi: 10.1007/s13300-016-0189-4. Epub 2016 
      Aug 8.